Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2017

01-02-2017

Evaluation of role of FV, FVIII and APLAs in the pathogenesis of APCR in FV Leiden negative DVT patients: a study in India

Authors: Amit Sharma, Kanwaljeet Singh, Arijit Biswas, Ravi Ranjan, Kamal Kishor, Ravi Kumar, Hareram Pandey, Vineet Kumar Kamal, Renu Saxena

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2017

Login to get access

Abstract

Resistance to APC (APCR) is a very important cause of thrombophilia and most frequently caused by the Leiden mutation. APCR is also seen in the absence of FV Leiden and associated with elevated levels of factor V (FV), factor VIII (FVIII) and antiphospholipid antibodies (APLAs). The aim of this prospective case control study was to find out the frequency and role of FV, FVIII and APLAs in the pathogenesis of APCR in FV Leiden negative deep vein thrombosis (DVT) patients in India. A total 30 APCR positive and FV Leiden negative patients with DVT and similar number of age and sex matched healthy controls were recruited. Significantly higher mean FVIII levels were observed in patients as compared to controls [patients: 132.3 ± 30.7 IU/ml, controls: 117.5 ± 17.7 IU/ml, p = 0.025]. A significant negative correlation was also observed between FVIII and APC ratio (Pearson correlation = 0.368, p = <0.001). Mean FV levels in patients [107.1 ± 13.1 IU/ml] and controls [102 ± 11.9 IU/ml] were not statistically significant (p = 0.119). Anti β2 glycoprotein I (Anti-β2-GPI, IgG) showed significant association with APCR phenotype (p = 0.050), unlike other factors such as protein C, protein S, lupus anticoagulant and anticardiolipin antibodies. The strong association of FVIII and anti-β2 GPI (IgG) antibodies with APCR phenotype is suggestive of incorporation of these factors in APCR positive DVT patients in the absence of FV Leiden mutation in India. However more studies in large sample size are required for setting up the proper investigation protocol in these patients.
Literature
1.
go back to reference Kalafatis M, Rand MD, Mann KG (1994) The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269(50):31869–31880PubMed Kalafatis M, Rand MD, Mann KG (1994) The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269(50):31869–31880PubMed
2.
go back to reference Svensson PJ, Dahlback B (1994) Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330(8):517–522CrossRefPubMed Svensson PJ, Dahlback B (1994) Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330(8):517–522CrossRefPubMed
3.
go back to reference Bertina RM, Koeleman BP, Koster T (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475):64–67CrossRefPubMed Bertina RM, Koeleman BP, Koster T (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475):64–67CrossRefPubMed
4.
go back to reference De Ronde H, Bertina RM (1994) Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 72(6):880–886PubMed De Ronde H, Bertina RM (1994) Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 72(6):880–886PubMed
5.
go back to reference Sharma A, Bhakuni T, Biswas A, Ranjan R, Kumar R, Kishore K, Mahapatra M, Jairajpuri MA, Saxena R (2015) Prevalence of FV genetic variants associated with Indian APCR contributing to thrombotic risk. Clin Appl Thromb Hemost. doi:10.1177/1076029615623376 Sharma A, Bhakuni T, Biswas A, Ranjan R, Kumar R, Kishore K, Mahapatra M, Jairajpuri MA, Saxena R (2015) Prevalence of FV genetic variants associated with Indian APCR contributing to thrombotic risk. Clin Appl Thromb Hemost. doi:10.​1177/​1076029615623376​
6.
go back to reference Williamson D, Brown K, Luddington R, Baglin C, Baglin T (1998) Factor V Cambridge: a new mutation (Arg306Thr) associated with resistance to activated protein C. Blood 91(4):1140–1144PubMed Williamson D, Brown K, Luddington R, Baglin C, Baglin T (1998) Factor V Cambridge: a new mutation (Arg306Thr) associated with resistance to activated protein C. Blood 91(4):1140–1144PubMed
7.
go back to reference Chan WP, Lee CK, Kwong YL, Lam CK, Liang R (1998) A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 91(4):1135–1139PubMed Chan WP, Lee CK, Kwong YL, Lam CK, Liang R (1998) A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 91(4):1135–1139PubMed
8.
go back to reference Saenz AJ, Johnson NV, Van Cott EM (2011) Acquired activated protein c resistance caused by lupus anticoagulants. Am J Clin Pathol 136(3):344–349CrossRefPubMed Saenz AJ, Johnson NV, Van Cott EM (2011) Acquired activated protein c resistance caused by lupus anticoagulants. Am J Clin Pathol 136(3):344–349CrossRefPubMed
9.
go back to reference Luddington R, Jackson A, Pannerselvam S, Brown K, Baglin T (2000) The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 83(2):204–208PubMed Luddington R, Jackson A, Pannerselvam S, Brown K, Baglin T (2000) The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 83(2):204–208PubMed
10.
go back to reference Brugge JM, Tans G, Rosing J, Castoldi E (2006) Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels. Thromb Haemost 95:236–242PubMed Brugge JM, Tans G, Rosing J, Castoldi E (2006) Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels. Thromb Haemost 95:236–242PubMed
11.
go back to reference Castoldi E, Rosing J (2010) APC resistance: biological basis and acquired influences. J Thromb Haemost 8(3):445–453CrossRefPubMed Castoldi E, Rosing J (2010) APC resistance: biological basis and acquired influences. J Thromb Haemost 8(3):445–453CrossRefPubMed
12.
go back to reference Henkens CM, Bom VJJ, van der Meer J (1995) Lowered APC sensitivity ratio related to increased factor VIII—clotting activity. Thromb Haemost 74(4):1198–1199PubMed Henkens CM, Bom VJJ, van der Meer J (1995) Lowered APC sensitivity ratio related to increased factor VIII—clotting activity. Thromb Haemost 74(4):1198–1199PubMed
13.
go back to reference Ehrenforth S, Radtke KP, Scharrer I (1995) Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 74(2):797–798PubMed Ehrenforth S, Radtke KP, Scharrer I (1995) Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 74(2):797–798PubMed
14.
go back to reference Gardiner C, Cohen H, Jenkins A, Machin SJ, Mackie IJ (2006) Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay. Blood Coagul Fibrinolysis 17(6):477–483CrossRefPubMed Gardiner C, Cohen H, Jenkins A, Machin SJ, Mackie IJ (2006) Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay. Blood Coagul Fibrinolysis 17(6):477–483CrossRefPubMed
15.
go back to reference Martinuzzo M, Forastiero R, Adamczuk Y, Cerrato G, Carreras LO (1996) Activated protein C resistance in patients with anti-beta 2 glycoprotein I antibodies. Blood Coagul Fibrinolysis 7(7):702–704CrossRefPubMed Martinuzzo M, Forastiero R, Adamczuk Y, Cerrato G, Carreras LO (1996) Activated protein C resistance in patients with anti-beta 2 glycoprotein I antibodies. Blood Coagul Fibrinolysis 7(7):702–704CrossRefPubMed
16.
go back to reference Zoller B, Svensson PJ, He X, Dahlback B (1994) Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94(6):2521–2524CrossRefPubMedPubMedCentral Zoller B, Svensson PJ, He X, Dahlback B (1994) Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94(6):2521–2524CrossRefPubMedPubMedCentral
17.
go back to reference Biswas A, Bajaj J, Ranjan R, Meena A, Akhter MS, Yadav BK, Sharma V, Saxena R (2008) Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian–Indian patients with deep vein thrombosis? Clin Chim Acta 392(1–2):21–24CrossRefPubMed Biswas A, Bajaj J, Ranjan R, Meena A, Akhter MS, Yadav BK, Sharma V, Saxena R (2008) Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian–Indian patients with deep vein thrombosis? Clin Chim Acta 392(1–2):21–24CrossRefPubMed
18.
go back to reference Kamphuisen PW, Eikenboom JC, Bertina RM (2001) Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 21:731–738CrossRefPubMed Kamphuisen PW, Eikenboom JC, Bertina RM (2001) Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 21:731–738CrossRefPubMed
19.
go back to reference Graf LL, Welsh CH, Qamar Z, Marlar RA (2003) Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol 119(1):52–60CrossRefPubMed Graf LL, Welsh CH, Qamar Z, Marlar RA (2003) Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol 119(1):52–60CrossRefPubMed
20.
go back to reference Laffan MA, Manning R (1996) The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 7(8):761–765CrossRefPubMed Laffan MA, Manning R (1996) The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 7(8):761–765CrossRefPubMed
21.
go back to reference Tosetto A, Simioni M, Madeo D, Rodeghiero F (2004) Intraindividual consistency of the activated protein C resistance phenotype. Br J Haematol 126(3):405–409CrossRefPubMed Tosetto A, Simioni M, Madeo D, Rodeghiero F (2004) Intraindividual consistency of the activated protein C resistance phenotype. Br J Haematol 126(3):405–409CrossRefPubMed
22.
go back to reference Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM (2000) Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 20(5):1382–1386CrossRefPubMed Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM (2000) Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 20(5):1382–1386CrossRefPubMed
23.
go back to reference O’Donnell J, Mumford AD, Manning RA, Laffan M (2000) Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 83(1):10–13PubMed O’Donnell J, Mumford AD, Manning RA, Laffan M (2000) Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 83(1):10–13PubMed
24.
go back to reference Roelse JC, Koopman MM, Buller HR, ten Cate JW, Montaruli B, van Mourik JA, Voorbert J (1996) Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. Br J Haematol 92(3):740–743CrossRefPubMed Roelse JC, Koopman MM, Buller HR, ten Cate JW, Montaruli B, van Mourik JA, Voorbert J (1996) Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. Br J Haematol 92(3):740–743CrossRefPubMed
25.
go back to reference Brummer J, Groth J, Flayeh R, Wagener C, Jung R (2002) Absence of mutations at the APC interacting sites of factor VIII in Caucasians. Thromb Haemost 87(1):170PubMed Brummer J, Groth J, Flayeh R, Wagener C, Jung R (2002) Absence of mutations at the APC interacting sites of factor VIII in Caucasians. Thromb Haemost 87(1):170PubMed
26.
go back to reference Sedano-Balbas S, Lyons M, Cleary B, Murray M, Gaffney G, Maher M (2011) Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women. J pregnancy doi:10.1155/2011/232840 PubMedPubMedCentral Sedano-Balbas S, Lyons M, Cleary B, Murray M, Gaffney G, Maher M (2011) Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women. J pregnancy doi:10.​1155/​2011/​232840 PubMedPubMedCentral
27.
go back to reference Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y (2005) Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 51(3):545–552CrossRefPubMed Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y (2005) Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 51(3):545–552CrossRefPubMed
28.
go back to reference Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M, David M, Andrew ME (2001) Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 97(4):844–849CrossRefPubMed Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M, David M, Andrew ME (2001) Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 97(4):844–849CrossRefPubMed
29.
go back to reference Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, Iwatani Y, Kanakura Y (2002) Acquired activated protein C resistance is associated with the coexistence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 118(2):577–583CrossRefPubMed Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, Iwatani Y, Kanakura Y (2002) Acquired activated protein C resistance is associated with the coexistence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 118(2):577–583CrossRefPubMed
Metadata
Title
Evaluation of role of FV, FVIII and APLAs in the pathogenesis of APCR in FV Leiden negative DVT patients: a study in India
Authors
Amit Sharma
Kanwaljeet Singh
Arijit Biswas
Ravi Ranjan
Kamal Kishor
Ravi Kumar
Hareram Pandey
Vineet Kumar Kamal
Renu Saxena
Publication date
01-02-2017
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2017
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1469-6

Other articles of this Issue 2/2017

Journal of Thrombosis and Thrombolysis 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.